Efficacy of Electrochemotherapy in the Treatment of Cutaneous Melanoma Metastases and Rare Non-melanoma Skin Cancer

We aimed to verify the clinical efficacy and safety of the electrochemotherapy in melanoma metastases and in cases of rare non-melanoma tumors that were difficult to treat for the specific anatomical site or for patient comorbidities. We treated 68 patients (699 cutaneous nodules), 44 patients with...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2020-11, Vol.40 (11), p.6485-6492
Main Authors: Borgognoni, Lorenzo, Pescitelli, Leonardo, Gerlini, Gianni, Brandani, Paola, Gelli, Riccardo, Giannotti, Vanni, Bellucci, Francesco, Sestini, Serena
Format: Article
Language:English
Subjects:
Adult
Bleomycin - administration & dosage
Cancer
Carcinoma, Merkel Cell
Chemotherapy
Electrochemotherapy
Female
Humans
Italy - epidemiology
Male
Melanoma
Melanoma - pathology
Melanoma - therapy
Melanoma, Cutaneous Malignant
Metastases
Metastasis
Middle Aged
Neoplasms, Second Primary - pathology
Neoplasms, Second Primary - therapy
Nevus
Nodules
Patients
Remission Induction
Sarcoma
Skin cancer
Skin Neoplasms - pathology
Skin Neoplasms - therapy
Thyroid
Thyroid carcinoma
Treatment Outcome
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to verify the clinical efficacy and safety of the electrochemotherapy in melanoma metastases and in cases of rare non-melanoma tumors that were difficult to treat for the specific anatomical site or for patient comorbidities. We treated 68 patients (699 cutaneous nodules), 44 patients with metastatic melanomas and 24 patients with non-melanoma tumors, at the Melanoma & Skin Cancer Unit, Florence, Italy. We obtained an objective response of 89.7% (88.6% in melanomas and 91.7% in non-melanoma tumors), complete response 54.4% and partial response 35.3%. This study showed that electrochemotherapy is effective in the treatment of melanoma metastases and in rare types of non-melanoma tumors. In particular, we successfully treated rare tumors as angiosarcoma, pleomorphic sarcoma, myxofibrosarcoma, sarcoma di Kaposi, porocarcinoma, sebaceous carcinoma, Merkel cell carcinoma, malignant blue nevus, undifferentiated epitheliomorphic cell neoplasia and metastases from thyroid carcinoma. No serious adverse events were observed.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14670